| From: jmhollen | 8/2/2005 1:29:11 PM | | | | | | PLEASE NOTE: The quotes screw-up on mafia.com is a MegaOpportunity for everyone, IMHO.
I also expect that we will see RTQs & Level-II for NNVC in the immediate future.
My 'reco' would be "..collect and hold.."!!!
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: canbballtrader who wrote (42) | 8/2/2005 2:44:30 PM | | From: jmhollen | | | | Subject 55842
mafia.ocm = pinksheets.com. Less keystrokes, and it makes fun of the 'Streeter Stock' Snobs around here.....
NNVC is in the middle of their go-to-OTCBB audit, and blew off updating Pinksheets, so Pinksheets retaliated (..bunch of azzholes..) by stopping their quotes with no warning.
Free RealTime.com will give you Time & Sales on NNVC (..paying for FRT Express is recommended..), and you can interpolate from that. I just bought 30K at 0.018.
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: rrufff who wrote (44) | 8/2/2005 5:24:53 PM | | From: jmhollen | | | | They're flying under the radar, doing the audit, and getting new products ready for launch.... ..Sounds like we'll get hit with a barrage next month....
Buy while the mafia.com quotes are hosed, when they're back (..with RTQs and L-II, I hope..) it should rebound quickly...
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/3/2005 12:48:43 PM | | | | | | "..Wheeeeeeeeeeeeeeeeeeeeeeeeee.......... ..I snagged another 10K for $0.175 during the noon sale...........
This is going to be fun when they get the mafia.com quotes fixed....
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 8/4/2005 11:27:34 AM | | | | | | NanoViricides Retains Auditor in Preparation of Filing Form 10-SB
Thursday August 4, 11:14 am ET
NEW YORK--(BUSINESS WIRE)--Aug. 4, 2005--NanoViricides, Inc. (Pink Sheets:NNVC - News; the "Company"), announced today that it had retained Bloom & Co., LLP of Hempstead, New York as its independent auditors, in anticipation of filing Form 10-SB and being quoted on the OTC bulletin board quotation system.
Commenting upon the retention, Leo Ehrlich, NanoViricides' Chief Financial Officer stated, "this is a very exciting time for NanoViricides. Retaining PCAOB registered auditors such as Bloom & Company will enable the Company to complete its first ever audit, an important step in our goal of becoming a reporting company. Upon completion of the Company's audited financial statements, we anticipate immediately filing a Form 10-SB to commence reporting obligations with the Securities and Exchange Commission. Becoming a reporting company with the objective of having our stock quoted on the OTC Bulletin Board is a positive step for the company and for our shareholders."
About NanoViricides - nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the NanoViricide(TM) particle, destroying it. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and market its products to major pharmaceutical companies.
Contact:
NanoViricides, Inc., New York
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com
or
Anil R. Diwan, Ph.D.
adiwan@snet.net
Source: NanoViricides, Inc.
biz.yahoo.com |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/4/2005 7:40:01 PM | | | | | | I found this a rather interesting read: nanoviricides.com
One of our crew who is a Doctor currently in surgical practice is going to do a little mining from his end. So, we'll see what his opinions about the potential therapies are shortly.
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 8/5/2005 3:38:52 PM | | | | | | Missed opportunities in nano
August 05, 2005
Nanotechnology companies are missing opportunities to help corporate buyers integrate nanoscale components into advanced products, experts told UPI's Nano World.
[Snip]
Lux Research sees nanotech services emerging in healthcare and life sciences, particularly in making existing blockbuster drugs more effective. For instance, Abraxane is made of nanoparticles containing the tumor-fighting drug paclitaxel bound to albumin protein. Abraxane can be taken without the toxic solvents normally used with paclitaxel, which means more of the drug can be taken with fewer side effects.
Lackner noted that Debiopharm in Lausanne, Switzerland, has partnered with NanoCarrier in Tokyo to reformulate their cancer treatment Eloxatin. NanoCarrier's micellar nanoparticles could "allow Debiopharm to extend the lifetime of its cash cow, which generated $1.5 billion in revenue in 2004," he said.
"More pharma giants will seek such capabilities as the impact of initial successes like American Pharmaceutical Partners' Abraxane kicks in and as reformulators like Elan deliver more winning products," Lackner added. "Companies that enter this underserved field with low-cost deals to prove their worth will transform themselves into long-term partners deserving premium prices."
physorg.com |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: donpat | 8/6/2005 8:17:56 AM | | | | | | HIV 'could destroy cancer cells'
US scientists hope to be able to use a harmless form of the Aids virus to seek and destroy cancer cells.
A University of California team found an "impotent" version of HIV, with the disease-causing parts of it removed, tracked down cancer cells in mice.
The next step would be to insert a gene into the virus that would kill the cancer upon contact.
The team told Nature Medicine more safety studies were needed before such a method could be tested in humans.
Gene therapy
The mice they studied had a form of skin cancer, called melanoma, that had spread to the lungs.
In the laboratory, the scientists took HIV and removed the parts of the virus that causes disease.
They then stripped off the virus' outer coat and redressed it with the outer suit of another virus.
By doing this, the researchers had changed the target of the virus.
HIV normally infects immune cells called T cells. The new outer coat instead directed HIV to hunt down molecules present on cancer cells, called P-glycoproteins.
The scientists also added a substance to the virus that would make it visibly glow when looked at with a special camera so they could track where it travelled once injected into the mice.
Researcher Dr Irvin Chen, from UCLA's Aids Institute, said: "The virus travelled through the bloodstream and homed straight to the cancer cells in the lungs, where the melanoma had migrated.
"Gene therapy has been hampered by the lack of a good carrier.
"Our approach proves that it is possible to develop an effective carrier and reprogram it to target specific cells in the body."
Beating cancer's spread
His team is planning to see whether the virus could carry a therapeutic gene to the precise location of the cancer.
As well as controlling cancer, they hope this technique might be useful for treating genetic diseases.
Dr Georges Vassaux, from Cancer Research UK's clinical centre at Barts and The London, said: "This is the first time that a vector - or delivery system - for gene therapy has targeted a tumour in such a specific manner.
"This means the technique could be used to use gene therapy in cases where cancer has spread around the body.
"So far gene therapy has been successfully used only on tumours that are confined to their original location."
He said there had been concerns that such methods might cause leukaemia in normal cells.
"As the team has managed to target the therapy to cancer cells, it looks as though a hazard associated with the use of integrative viruses may have been overcome," he said.
news.bbc.co.uk
newsroom.ucla.edu
|
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
